Drugs / D46/NS2/N/ΔM2-2-HindIII
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03102034 | Apr 2017 → May 2018 | respiratory syncytial virus infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | D46/NS2/N/ΔM2-2-HindIII | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03102034 ↗ |
| Modality | Vaccine | “Live RSV vaccine D46/NS2/N/ΔM2-2-HindIII” PMID 32006006 ↗ Jun 2020 |
| Route | Intranasal | “RSV-seronegative children aged 6-24 months received 1 intranasal dose (105 plaque-forming units [PFUs] of D46/NS2/N/ΔM2-2-HindIII [n = 21] or placebo [n = 11])” PMID 32006006 ↗ Jun 2020 |